Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hyperglycemia

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Hypoglycemia

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ioannidis' "The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-Analyses" 10 Years Later: An Update and Real-World Experience.

American journal of therapeutics·2025

Same author

Beta-Adrenergic Blockers for Acute Myocardial Infarction: 50 years of Expert Opinions in Cecil Textbook of Medicine.

American journal of therapeutics·2025

Same author

Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia.

JAMA psychiatry·2024

Same author

Dopamine D2 receptor antagonism of antipsychotics and the risk of death due to choking.

Psychiatry research·2024

Same author

Premature Closure of Scientific Thinking: Deaths Due to Chloroquine and Hydroxychloroquine Used for COVID-19 Infection.

American journal of therapeutics·2024

Same author

Pharmacological Management of Cholera: A Century of Expert Opinions in Cecil Textbook of Medicine.

American journal of therapeutics·2023

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

Rapidly developing hyperglycemia during treatment with olanzapine.

Izchak Kohen¹, Mordechai Gampel, Lakshmi Reddy

¹North Shore-Long Island Jewish Health System, The Zucker Hillside Hospital, Geriatric Psychiatry Division, Glen Oaks, NY 11004, USA. ikohen@nshs.edu

The Annals of Pharmacotherapy

|March 28, 2008

Summary

Olanzapine rapidly caused hyperglycemia in an elderly patient within days of treatment initiation. This adverse drug event, likely linked to olanzapine, highlights the need for vigilant monitoring in geriatric patients.

More Related Videos

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Related Experiment Videos

Last Updated: Jul 6, 2026

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Area of Science:

Geriatric Medicine
Pharmacology
Endocrinology

Background:

Olanzapine is an atypical antipsychotic used for behavioral disturbances and psychosis.
Hyperglycemia is a known potential side effect of atypical antipsychotics, often associated with weight gain.
The typical onset of hyperglycemia with olanzapine is not well-defined in the literature.

Observation:

An 89-year-old male patient with dementia developed acute hyperglycemia (fasting blood glucose 138 mg/dL) three days after initiating olanzapine therapy.
The hyperglycemia resolved upon olanzapine discontinuation and recurred upon rechallenge with the medication (fasting blood glucose 150 mg/dL).
The patient also experienced worsening confusion, lethargy, and acute renal failure concurrently with the recurrent hyperglycemia.

Findings:

A probable causal relationship was established between olanzapine treatment and the rapid onset of hyperglycemia.
This case represents one of the fastest onsets of drug-induced hyperglycemia reported with olanzapine.
Animal studies suggest olanzapine and clozapine can rapidly impair insulin sensitivity in a dose-dependent manner.

Implications:

Clinicians should be aware of the potential for rapid hyperglycemia development in elderly patients treated with olanzapine.
Close monitoring of blood glucose levels is crucial in geriatric patients initiating olanzapine therapy.
The findings suggest that weight gain may not be a prerequisite for olanzapine-induced hyperglycemia.